Drugs / Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04963413 | Jan 2022 → Sep 2023 | glioblastoma | University of Florida | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04963413 ↗ |
| Modality | Cell therapy | “Autologous DCs derived from PBMC loaded with RNA” NCT04963413 ↗ |